Trial Profile
A study evaluating clinical and radiological activity of Natalizumab in patients with relapsing remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology